AI Summary
This article discusses a phase II clinical trial showing that the drug olaparib may be effective in treating biochemically recurrent prostate cancer in men with mutations in genes like BRCA2, without the need for hormone therapy. This suggests that olaparib could be a potentially precise treatment option for this specific group of patients.
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients.